Does ALPELISIB Cause Malignant neoplasm progression? 497 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 497 reports of Malignant neoplasm progression have been filed in association with ALPELISIB (PIQRAY). This represents 5.9% of all adverse event reports for ALPELISIB.
497
Reports of Malignant neoplasm progression with ALPELISIB
5.9%
of all ALPELISIB reports
136
Deaths
99
Hospitalizations
How Dangerous Is Malignant neoplasm progression From ALPELISIB?
Of the 497 reports, 136 (27.4%) resulted in death, 99 (19.9%) required hospitalization, and 13 (2.6%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ALPELISIB. However, 497 reports have been filed with the FAERS database.
What Other Side Effects Does ALPELISIB Cause?
Hyperglycaemia (1,575)
Rash (1,393)
Diarrhoea (1,336)
Blood glucose increased (1,105)
Death (921)
Nausea (860)
Fatigue (817)
Decreased appetite (546)
Weight decreased (508)
Vomiting (479)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which ALPELISIB Alternatives Have Lower Malignant neoplasm progression Risk?
ALPELISIB vs ALPHA.-LIPOIC ACID
ALPELISIB vs ALPHA.-TOCOPHEROL
ALPELISIB vs ALPHA.-TOCOPHEROL, D-
ALPELISIB vs ALPHA.-TOCOPHEROL, DL-
ALPELISIB vs ALPHA.1-PROTEINASE INHIBITOR HUMAN